Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 14/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 14/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 11/20 | 0.44 |
| ▸ | PI4KA | P42356 | 6/20 | 0.43 |
| ▸ | PI4K2B | Q8TCG2 | 6/20 | 0.43 |
| ▸ | PI4K2A | Q9BTU6 | 6/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 6/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22326710 | 0.85 | ADORA2A (0.46) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL22326776 | 0.79 | ADORA2A (0.46) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL22326770 | 0.77 | ADORA2A (0.47) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL18520815 | 0.75 | ADORA2A (0.64) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL22571152 | 0.71 | PI4KA (0.50) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL18526490 | 0.71 | ADORA2A (0.69) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL18510391 | 0.71 | ADORA2A (0.67) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL22381523 | 0.70 | ADORA2A (0.56) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL24222092 | 0.69 | ADORA2A (0.68) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL22571151 | 0.67 | ADORA2A (0.70) | ADORA2AADORA1ADORA2BPI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-06 | — | — | US | disclosed |
| US-20210106607-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-15 | — | — | US | disclosed |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210106607-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | ADORA2A 385/4885ADORA1 446/4885ADORA2B 827/4885 |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | STING1, TLR9, CGAS | ADORA2A 385/4885ADORA1 446/4885ADORA2B 827/4885 |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | ADORA2A 73/4885ADORA1 32/4885ADORA2B 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.